Stockwinners Market Radar for June 15, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:20 EDT Diginex and EQUOS rebrand to EQONEX - Diginex Limited announced that it is unifying its businesses under the brand, EQONEX. The rebrand brings together under the EQONEX Group brand, its cryptocurrency exchange, custody platform, multi-venue trading business, over-the-counter offering, its asset management solution, securitization business and the upcoming investment products and borrowing and lending businesses. EQUOS, the cryptocurrency exchange will be known as EQONEX and Diginex Capital, the digital asset securitization business will be rebranded to EQONEX Capital. The investment products business will be called EQONEX Investment Products and the anticipated borrowing and lending platform will become EQONEX Lending. Diginex Access, the multi-venue trading platform, will rebrand to Access Trading. Digivault, the UK Financial Conduct Authority-registered crypto-asset custodian, will continue to operate under its current name. Bletchley Park, the crypto fund of funds, will also operate under its current name. The company's corporate name will remain Diginex Limited and the company will continue to trade on the Nasdaq Stock Exchange as Diginex Limited, pending a resolution to rename the corporate entity at the company's AGM later this year. The rebrand follows the divestment of Diginex Solutions, the ESG blockchain solutions company, in May 2020 and the impending lapse of the license to use the "Diginex" brand at the end of the month.

18:26 EDT Akamai CEO: Revenue from security is growing - In an interview on CNBC's Mad Money, Dr. Tom Leighton said security is now 37% of Akamai's revenue. The company takes a different approach to cyber security, he noted. The way enterprises defend themselves digitally is poor, Leighton argued, noting they have to adopt multi-factor authentication. The government can and should help companies set a baseline of security standards, he said.

18:08 EDT AT&T sees C-band spectrum covering 200M people by end of 2023 - AT&T CFO Pascal Desroches provided an update to shareholders at the Credit Suisse Communications conference. Desroches said that AT&T's network is performing as well as it ever has and that as the company accelerates its deployment of C-band spectrum, it expects to cover 200M people by the end of 2023. Desroches indicated that the company's outlook includes expectations for continued elevated wireless competition and thus recent promotional activity by other wireless providers does not come as a material surprise. Desroches also said the company's plan to double the size of AT&Ts fiber footprint to about 30M customer locations by year-end 2025 should open up new use cases and opportunities given the company's integrated fiber deployment strategy and penetration trends in areas where fiber has already been deployed.

18:00 EDT Rio Tinto, ARENA partner to study using hydrogen to reduce carbon emissions - Rio Tinto has partnered with the Australian Renewable Energy Agency to study whether hydrogen can replace natural gas in alumina refineries to reduce emissions. Rio Tinto will conduct a $1.2 million feasibility study, equally funded with ARENA through a $580,000 grant, into using clean hydrogen to replace natural gas in the calcination process of refining at the Yarwun aumina refinery in Gladstone. The study program includes work to be done at Rio Tinto's Bundoora Technical Development Centre in Melbourne, where Rio Tinto's in-house development capability has now been extended to hydrogen.

17:21 EDT Vail Resorts CEO sells 91.7K shares of common stock - In a regulatory filing, Vail Resorts disclosed that its CEO Robert Katz sold 91.7K shares of common stock on June 14th in a total transaction size of $29.5M, reducing his stake by about 26%.

17:04 EDT Oxford Industries increases quarterly dividend 14% - Oxford Industries announced that its board declared a cash dividend of 42c per share on common stock, a 14% increase from the previous level of 37c per share. The dividend is payable on July 30 to shareholders of record as of the close of business on July 16.

16:57 EDT MiMedx says JID-published data highlights benefits in dHACM - The company states: "MiMedx Group announced publication of its peer-reviewed study in the Journal of Investigative Dermatology Innovations, addressing the potential benefit of MIMEDX Purion processed dehydrated human amnion/chorion membrane, or dHACM, to combat complications stemming from excessive fibrosis, a pathological process central to a number of serious unmet medical needs. It is estimated that worldwide more than 100M people suffer from pathological scar formation annually, including hypertrophic and keloid scar formation, with long-term effects ranging in severity from minor cosmetic defects to significantly compromised tissue architecture and impaired function across a number of conditions. MIMEDX Purion processed dHACM has been used extensively for the treatment of multiple acute and chronic conditions ranging from diabetic foot ulcers and significant burn injuries to musculoskeletal and sports medicine applications. Clinical evidence suggests that using these products in treatment regimens not only accelerates healing, but anecdotally, also improves the quality of the repair as evidenced by reduced scar tissue formation. Amniotic membrane has long been thought to possess anti-scarring properties; however, the mechanism to achieve a response is not fully understood. Therefore, this study, authored by Sarah Moreno, Michelle Massee, and Thomas J. Koob, Ph.D., was intended to explore the potential mechanism of action by which dHACM affects fibrotic pathways."

16:49 EDT Platinum Equity to acquire McGraw Hill from Apollo Funds for $4.5B - Platinum Equity announced that it has entered into a definitive agreement to acquire McGraw Hill, from funds managed by affiliates of Apollo Global Management for a purchase price of approximately $4.5B. McGraw Hill CEO Simon Allen and his senior leadership team will continue to lead the business under Platinum's ownership. The sale is expected to be completed this summer, subject to customary closing conditions and regulatory approval.

16:46 EDT RA Capital reports 7.5% passive stake in Catabasis Pharmaceuticals - RA Capital disclosed a 7.5% stake in Catabasis Pharmaceuticals, which represents over 5.74M shares. The filing does not allow for activism. Shares of Catabasis Pharmaceuticals are up 27.5% after-hours.

16:37 EDT Leslie's CEO sells 475K shares of common stock - In a regulatory filing, Leslie's disclosed that its CEO Michael Egeck sold 475K shares of common stock on June 14th in a total transaction size of $12.75M, reducing his stake by about 24%.

16:35 EDT Titan International chairman comments on stockholder meeting results - Titan International announced the results from its annual stockholders' meeting. Morry Taylor, chairman of the Board, commented, "I have been doing these meetings for TWI since 1993. My fellow stockholders, this means I have seen a lot of different things over the years, and this year was the oddest. It even beat out the years of the steelworkers protest, and 'the Rubber Strike'. ISS came out with recommendations to withhold votes on all Board members except for our newest Board member, Laura Thompson. If this had happened, would anyone think this would be best for the Company or Titan's stockholders? It is very surprising that there are investors who think certain proposals are good for every company. Titan International, Inc is a manufacturer of farm and OTR wheels, tires and undercarriage products. There is no question Titan is the largest in North America, but it has significant foreign competition that we fight against. I should also point out that our U.S. government allows the U.S market to remain open, while the foreign markets are closed to our products. I want to thank all of our stockholders who supported the team at Titan. This year is going to be another important year for the Company and we believe the strong market will continue throughout 2022 and perhaps beyond. The proxy advisors were also upset that Titan didn't give enough information in the form of targets for management compensation. I mentioned this at the stockholder meeting. How can you give forward projection when in November 2020 OEMs were telling the world 5% growth in sales in 2021 and Titan Board of Directors in December approved a budget that had a sizeable financial increase in 2021, but by February there were sales increases of over 25% or more? Titan's business is increasing significantly as witnessed by our first quarter results. Everything is moving up because the price of corn and soybeans are high and I believe they will stay high in the foreseeable future. Paul Reitz, President and CEO, has a great team and they are doing the right things to drive the business. However, to ask them to get the projections right a year out is asking too much. It has been a long time since everything has lined up like this. We don't know when the peak will be, but I don't believe we are there yet, that's for sure! We are optimistic about the future. All Directors were reelected and all other proposals were approved with a majority vote. Hopefully, next year, the proxy advisor services can call or visit us and we can show them what makes Titan tick. Public companies don't all look alike. We look forward to sharing our progress as we move forward. I greatly appreciate your support of Titan."

16:32 EDT Capital One, Williams-Sonoma enter strategic partnership - Capital One Financial (COF) announced it has entered into a program agreement with Williams-Sonoma (WSM), becoming the exclusive long-term issuing partner for Williams-Sonoma's new co-brand and private-label credit card program. The partnership will include Williams Sonoma, Pottery Barn, Pottery Barn Teen, Pottery Barn Kids, West Elm and Mark & Graham and allow customers to shop and earn rewards across the family of brands. The new credit cards and loyalty enhancements are expected to launch before the end of 2021. In connection with the new Williams-Sonoma, Inc. credit card program, Capital One has entered into a definitive purchase and sale agreement under which it will acquire the existing portfolio of Williams-Sonoma, Inc. credit card accounts subject to the satisfaction or waiver of customary closing conditions. Over the coming months, more details will be provided to existing cardmembers on the transition to the new card program. Visa (V) will continue to be the exclusive network for the Williams-Sonoma credit card portfolio with the new co-brand credit card issued on its payment network

16:25 EDT Atara Biotherapeutics director buys 34.3K shares of common stock - In a regulatory filing, Atara Biotherapeutics disclosed that its Chief Commercial Officer Kristin Yarema bought 34.3K shares of common stock on June 11th in a total transaction size of $500K, boosting her stake by about 38%.

16:22 EDT Roblox falls after month-over-month decline in daily active users - Shares of Roblox moved lower after the company reported that May daily active users were 43M, up 28% from May of last year but down 1% from in April. Revenue is estimated to be between $149M- $151M for the month, up 123% - 126% year-over-year. Shares of Roblox are down 4% to $85.45 in after-hours trading.

16:18 EDT G-III Apparel COO Wayne Miller stepping down - G-III Apparel Group announced that, effective July 1, Wayne Miller will step down as the company's COO and will become a senior strategic advisor to the company. Miller will assist in the transition of his day-to-day responsibilities and advise the company on various aspects of corporate strategy.

16:17 EDT La-Z-Boy reports Q4 written same-store sales up 100% - Q4 Written same-store sales for the entire La-Z-Boy Furniture Galleries network doubled, increasing 100%.

16:17 EDT H&R Block raises quarterly dividend 4% to 27c per share - H&R Block announced that its Board of Directors increased the quarterly dividend by 4%, representing the fifth increase in the dividend in six years and a 35% total increase over that time frame. The quarterly cash dividend is now $0.27 per share, payable on July 1, 2021 to shareholders of record as of June 25, 2021. The Company has paid consecutive quarterly dividends since it became publicly traded in 1962. Future actions regarding dividends will be dependent upon the Board's approval following consideration of operating results, market conditions, and capital needs, among other factors. In fiscal 2021, the company repurchased 11.6 million shares for $188 million, at an average price of $16.29. Share repurchases made in the fourth quarter of fiscal 2021 totaled $38 million. Approximately $564 million remains under the company's current share repurchase authorization, which expires in June of 2022.

16:15 EDT W. R. Berkley raises quarterly dividend by 8% to 13c per share - The dividend will be paid on July 6, 2021 to stockholders of record at the close of business on June 25, 2021.

16:13 EDT Aptinyx says finalized design of Phase 2b program for NYX-783 in PTSD patients - The analyst says: "Aptinyx announced that it has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder, or PTSD, after having received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration . The company expects to initiate the Phase 2b program in the fourth quarter of 2021. Aptinyx also announced that, in its preparation for Phase 2b, it identified a statistical error made by the contract research organization that performed the statistical analysis of the previously completed exploratory Phase 2 study in PTSD. Accordingly, the company is providing updated statistical analysis for the exploratory Phase 2 study, which has no impact on the study conclusions... In the process of completing its in-depth data analysis to prepare for and finalize the design of the Phase 2b program for NYX-783, the company identified a statistical modeling error made by the CRO that performed the statistical analysis of the previously completed exploratory Phase 2 study. The error resulted from an incorrect analysis of variance in the mixed model for repeated measures statistical model. While there were no changes to the numerical improvements from baseline, the revised MMRM p-values are higher than previously reported in October 2020. The CRO confirmed the error in late May and reported the updated statistical analysis to the company in June."

16:10 EDT Oracle CTO Ellison says 'Oracle Database delivered solid revenue growth in FY21' - "The world's two most popular databases are the Oracle Autonomous Database and Oracle MySQL," said Oracle Chairman and CTO, Larry Ellison. "The Oracle Database once again delivered solid revenue growth in FY21. And while our Oracle Database business as measured by revenue currently dwarfs our MySQL database business-that is about to change because the latest version of Oracle MySQL has been upgraded to include a revolutionary new ultra-high-performance parallel processing query engine called HeatWave. Independent analysts have tested and confirmed that Oracle MySQL with HeatWave runs 10 to 100 times faster than Amazon's version of MySQL called Aurora. This technological breakthrough is causing several of Amazon's customers to start moving their Aurora workloads to Oracle MySQL. And industry analysts are telling us they are seeing a 10x increase in Oracle Cloud Infrastructure customer inquiries. Both the Oracle Autonomous Database and Oracle MySQL with HeatWave technology have captured the technology high-ground in the cloud database business-and that bodes well for the future of the Oracle Cloud."

16:08 EDT Oracle CEO says Q4 results 'absolutely outstanding' - "Our Q4 performance was absolutely outstanding with total revenue beating guidance by nearly $200 million, and non-GAAP earnings per share beating guidance by $0.24," said Oracle CEO, Safra Catz. "Our multi-billion dollar Fusion and NetSuite cloud applications businesses saw dramatic increases in their already rapid revenue growth rates: Fusion ERP was up 30% in Q3 and up 46% in Q4, Fusion HCM was up 23% in Q3 and up 35% in Q4, NetSuite was up 24% in Q3 and up 26% in Q4. Oracle Fusion is the world's biggest cloud ERP business; Oracle NetSuite is the world's second biggest cloud ERP business. Revenue from our Gen2 Cloud Infrastructure business including Autonomous Database grew over 100% in Q4. The accelerating growth rates of both our applications and infrastructure cloud businesses this year drove earnings per share growth up to 21% in FY21. That is the fourth consecutive year of double-digit earnings per share growth at Oracle Corporation."

16:07 EDT Spero initiates bcronchoalveolar lavage, renal impairment trials of SPR206 - Spero Therapeutics announced the initiation of two Phase 1 trials of SPR206, an intravenously -administered next-generation polymyxin product candidate. SPR206 was derived from Spero's potentiator platform and is being developed to treat serious multi-drug resistant (MDR) Gram-negative infections in the hospital setting. These trials, which are now open for enrollment, include a bronchoalveolar lavage clinical trial assessing the penetration of SPR206 into the pulmonary compartment and a renal impairment clinical trial. "SPR206 has the potential to treat serious infections in patients with limited therapeutic options, and the initiation of these Phase 1 trials represents an important step in its clinical development," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. "The preclinical and clinical data set supporting SPR206 demonstrates a favorable safety profile and potent activity against MDR and extensively drug resistant bacterial strains. We expect these newly initiated trials to build on prior results by providing crucial pharmacokinetic data. These PK data will inform the potential utility of SPR206 in specific tissue compartments and the design of future efficacy trials that will seek to address the urgent threat posed by MDR Gram-negative infections."

16:05 EDT Roblox reports 43M DAUs in May, up 28% y/y - Roblox released its May 2021 key metrics. Daily active users were 43.0 million, up 28% from May of last year and down 1% from 43.3 million in April 2021. Hours engaged were 3.2 billion, up 9% year over year and up 1% from 3.2 billion in April 2021. Bookings are estimated to be between $216 million and $219 million, up 24% - 26% year over year. Average Bookings per DAU are estimated to be between $5.02 and $5.09, down 2% - 3% year over year. Revenue is estimated to be between $149 million - $151 million, up 123% - 126% year over year.

16:01 EDT BlackRock and Cassini Systems announce strategic partnership - BlackRock and Cassini Systems, a leading provider of pre- and post-trade margin and collateral analytics for derivatives markets, announced that the two firms have entered into a strategic partnership to integrate Cassini analytics into BlackRock's Aladdin platform. The integration will allow mutual clients to factor margin-based analytics into their pre- and post-trade decision-making.

15:15 EDT Southwest says systems restored after 'unusual' issues - Southwest Airlines said via Twitter, "To be transparent, we were experiencing unusual system issues that down-line impacted our customer service channels. Our systems have now been restored."

15:09 EDT Canoo rallies after recommendation on Reddit's Wallstreetbets - Shares of Canoo are moving higher after a user in Reddit's Wallstreetbets forum recommended the name as both a short and long term "tremendous play." The electric vehicle startup is trading up 8%, or 74c, to $10.20 in afternoon trading. Reference Link

14:31 EDT Mallinckrodt's Stratatech granted FDA approval for thermal burn treatment - The Food and Drug Administration said it approved StrataGraft for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Thermal burns are typically caused by direct contact with an external heat source such as steam, scalding water, hot surfaces or fire. StrataGraft is produced from two kinds of human skin cells grown together to make a bi-layered construct. The FDA granted approval to Stratatech, a Mallinckrodt company.

13:55 EDT Lordstown says debut truck to price higher than expected at $55,000 - In a conversation with the Automotive Press Association, Lordstown Motors executives, according to Bloomberg, said the company's debut pickup truck will cost around $55,000, slightly higher than previously expected due to higher supply chain costs. The executives declined to comment on the SEC investigation.

13:32 EDT At Home Group postpones 2021 annual meeting of stockholders - At Home Group announced that due to the pending merger transaction with funds affiliated with Hellman & Friedman, the company will postpone its 2021 Annual Meeting of Stockholders. The Annual Meeting, which was scheduled to be held Wednesday, will be held in the event the H&F transaction is not approved or otherwise does not occur, in which case a new date for the Annual Meeting will be announced.

13:25 EDT PacWest Bancorp names Angela Kelley as EVP, general counsel - PacWest Bancorp announced the hiring of Angela Kelley as their new EVP, General Counsel and Corporate Secretary. She will also serve as the EVP, General Counsel for Pacific Western Bank, the wholly-owned banking subsidiary of the company. Most recently she served as the General Counsel and Corporate Secretary for NBT Bancorp, Inc. in Syracuse, New York.

13:23 EDT Lordstown President tells webcast production through May 2022 funded

12:56 EDT Nano Dimension granted U.S. patent for double-sided printed circuit board - The United States Patent and Trademark Office posted on its website that Nano Dimension has been granted a patent for double-sided and multilayered printed circuit board fabrication using inkjet printing.

12:52 EDT Upwork targeting long-term revenue of $1B+ in 2025 - Targeting long-term EBITDA 30%-35%, total gross margin 80%-85%. Comments taken from Investor Day presentation slides.

12:13 EDT American Express reports May net write-off rate 1.1% vs. 1.0% last month - Reports May 30 days past due loans as a percent of total 0.5% vs. 0.5% last month.

12:00 EDT BIT Mining Limited falls -9.5% - BIT Mining Limited is down -9.5%, or -86c to $8.24.

12:00 EDT BP Prudhoe Bay rises 8.4% - BP Prudhoe Bay is up 8.4%, or 42c to $5.40.

12:00 EDT Finance of America rises 26.4% - Finance of America is up 26.4%, or $1.93 to $9.23.

11:50 EDT DraftKings says Hindenburg short report written 'to drive down share price' - Contacted by The Fly following Hindenburg Research's short report claiming black market connections, a spokesperson for DraftKings said that, "This report is written by someone who is short on DraftKings stock with an incentive to drive down the share price. Our business combination with SBTech was completed in 2020. We conducted a thorough review of their business practices and we were comfortable with the findings. We do not comment on speculation or allegations made by former SBTech employees."

11:46 EDT DraftKings says Hindenburg short report written 'to drive down share price' - Contacting by The Fly following Hindenburg Research's short report claiming black market connections, a spokesperson for DraftKings said that, "This report is written by someone who is short on DraftKings stock with an incentive to drive down the share price. Our business combination with SBTech was completed in 2020. We conducted a thorough review of their business practices and we were comfortable with the findings. We do not comment on speculation or allegations made by former SBTech employees."

11:23 EDT Emmaus Life Sciences submits MAA to Swissmedic for Endari - Emmaus Life Sciences announced that it has received confirmation from the Swiss Agency for Therapeutic Products of Emmaus' application for Marketing Authorization for Endari in Switzerland. Swissmedic is responsible for the authorization and supervision of therapeutic products in Switzerland. In November 2020, Swissmedic granted Endari orphan drug status. Swissmedic's MA review and approval process typically takes 16 to 18 months. "We are looking forward to Swissmedic's review of our MA application for Endari, which represents another important step in our progress and commitment to reach and improve the lives of sickle cell disease patients internationally," said Yutaka Niihara, M.D., M.P.H., Chairman and CEO of Emmaus.

11:10 EDT Eton Pharmaceuticals trading resumes

10:50 EDT Charlotte's Web appoints Wes Booysen as CFO - Charlotte's Web Holdings (CWBHF) announced that Wessel Booysen has joined the company as CFO. Booysen has more than a decade of global executive leadership in finance, international expansion and strategic M&A at Molson Coors Beverage Company (TAP). He will help lead the company through its next phase of growth which includes broad international expansion. In his most recent leadership role at Molson Coors, ooysen was CEO and Managing Director in Melbourne, Australia leading the businesses in Asia Pacific and Africa.

10:28 EDT Eton Pharmaceuticals trading halted, news pending

10:11 EDT Popular originated $2.1B in loans under SBA paycheck protection program - Popular announced that, upon completion of the second round of the Paycheck Protection Program on May 31, 2021, it had processed nearly 50,000 loans, originating $2.1B in both rounds of the program. Popular indicated that, in the second PPP round, which began on January 19, the company processed approximately 20,500 loans totaling $673M throughout its footprint in Puerto Rico, the United States, and the U.S. Virgin Islands. Popular's average loan size was $32,800 compared to the national average of $42,000. In Puerto Rico, the average loan was $29,000. The businesses that benefitted from these PPP loans employ approximately 136,000 people across many industries including food and lodging, retail, health and social assistance, and professional services. Popular was the main bank in Puerto Rico in terms of loans processed in both PPP rounds, with a total of $1.7B or 62% of the total loans originated on the island.

10:01 EDT Apple Podcasts Subscriptions and channels now available worldwide - Apple announced Apple Podcasts Subscriptions, the global marketplace for premium podcast subscriptions, is now available. Apple said: "Starting today, listeners in more than 170 countries and regions can purchase subscriptions for individual shows and groups of shows through channels, making it easy to support their favorite creators, enjoy new content, and unlock additional benefits such as ad-free listening and early access, directly on Apple Podcasts."

10:00 EDT Washington REIT falls -7.1% - Washington REIT is down -7.1%, or -$1.90 to $24.93.

10:00 EDT Mayville Engineering rises 6.4% - Mayville Engineering is up 6.4%, or $1.19 to $19.88.

10:00 EDT X Financial rises 29.3% - X Financial is up 29.3%, or $2.41 to $10.63.

09:49 EDT Moderna, Magenta Investments partner to distribute Moderna's COVID-19 vaccine - Moderna and Magenta Investments announced a new agreement to distribute the Moderna COVID-19 Vaccine as well as Moderna's updated variant booster candidates, once authorized, in the United Arab Emirates in 2021 and 2022. "We welcome the opportunity to work alongside Magenta for the distribution of our vaccine in the UAE," said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. "Together with our partners, we hope to advance our goal to expand access to our vaccine globally, and support governments such as the UAE in protecting their citizens, residents and visitors against the pandemic."

09:47 EDT Ping Identity falls -6.3% - Ping Identity is down -6.3%, or -$1.54 to $23.02.

09:47 EDT Yirendai falls -7.7% - Yirendai is down -7.7%, or -40c to $4.78.

09:47 EDT Telus International rises 4.6% - Telus International is up 4.6%, or $1.42 to $32.38.

09:46 EDT Moderna, Magenta Therapeutics partner to distribute Moderna's COVID-19 vaccine - Moderna (MRNA) and Magenta Investments (MGTA) announced a new agreement to distribute the Moderna COVID-19 Vaccine as well as Moderna's updated variant booster candidates, once authorized, in the United Arab Emirates in 2021 and 2022. "We welcome the opportunity to work alongside Magenta for the distribution of our vaccine in the UAE," said Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. "Together with our partners, we hope to advance our goal to expand access to our vaccine globally, and support governments such as the UAE in protecting their citizens, residents and visitors against the pandemic."

09:43 EDT X Financial (Class A ADS) trading halted, volatility trading pause

09:31 EDT Nokia announces collaboration with HMD Global using IoT connectivity - Nokia announced it will collaborate with HMD Global using Nokia's Worldwide IoT Network Grid to enable "seamless global IoT connectivity for HMD's IoT solution for enterprises," the company said. The collaboration will allow enterprise customers of the HMD Connect Pro service to track and manage connected devices around the world. Ankur Bhan, Head of Network Function as a Service at Nokia, said: "Working with HMD Global we will provide a superior worldwide IoT network presence for a consistent level of customer support. The HMD Pro service will leverage an ever-growing connectivity ecosystem. Nokia WING provides a borderless connected world for IoT reducing complexity for enterprises and allowing them the highest level of control over their assets wherever they are."

09:23 EDT BrainStorm expands portfolio of patents related to NurOwn - Brainstorm Cell Therapeutics announced the grant and/or allowance of a series of patents and patent applications. These patents and patent applications, which were granted/allowed in 2020 and 2021, are expected to provide broad protection for Brainstorm's proprietary NurOwn, or MSC-NTF cells, technology in territories including the U.S., E.U., Canada, Israel and Hong Kong.

09:22 EDT ENGlobal delivers final process module for hydrogen plant - ENGlobal reported that it has delivered the last of 24 process modules being used to construct a complete hydrogen production unit located on an 800 acre-plus site in Hugoton, Kansas. Following several months of additional fabrication and construction and start-up support, ENGlobal's customer, Seaboard Energy, will use the hydrogen from this unit to begin operating a renewable diesel facility with a capacity of 6,500 barrels per day.

09:21 EDT Puzzle Wealth Solutions' team joins LPL Financial's platforms - LPL Financial announced that the team at Puzzle Wealth Solutions has joined LPL Financial's broker-dealer, hybrid registered investment advisor and custodial platforms. They are aligned with Gladstone Wealth Partners. They join LPL from UBS Financial Services.

09:19 EDT NeuroMetrix announces Quell technology to be used to evaluate NMOSD in trial - NeuroMetrix announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation is an effective, acceptable and feasible method of pain relief in patients with NMOSD. The current trial will enroll 46 patients with NMOSD. The subjects will be randomized to an active or sham Quell device for 4 weeks. All subjects will then proceed into a 4-week open-label active treatment phase. The primary outcome measure is the baseline to 4-week change in pain intensity using the 11-point numerical pain scale. Study details are available here. "We are pleased to support Dr. Levy and his colleagues in this clinical trial. NMOSD is a disabling disease without safe and effective treatment options," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "This rigorous randomized controlled trial will add to the growing body of clinical data on the utility of Quell technology in chronic pain conditions with a neuropathic pain component. There are significant unmet clinical needs in the treatment of neuropathic pain that Quell may be able to eventually address."

09:17 EDT Save Foods announces expansion of use of SavePROTECT across all SiCar Farms - Save Foods announces that SiCar Farms has recently directed that Save Foods' post-harvest treatment, SavePROTECT, be used across all its packing houses with the intention of supplying retail customers with long-lasting limes that simultaneously leads to reducing waste. Dan Sztybel, the chief executive officer of Save Foods Ltd., added, "More than 1.4 million tons of lime were consumed in the United States in 2018, and we look forward to working with SiCar as they work to expand their share of this market. The benefits that Save Foods' products provide companies like SiCar go beyond improved quality, longer shelf life and reduced waste. These qualities potentially translate into a broader sales horizon, higher revenue potential and reduced expenses, making Save Foods-treated produce the natural choice across the distribution chain."

09:16 EDT GoDaddy announces launch of GoDaddy Payments - GoDaddy announced the launch of GoDaddy Payments, a new payments solution that enables GoDaddy Websites + Marketing and Managed WordPress WooCommerce customers to handle all of their commerce transactions directly through GoDaddy. GoDaddy Payments is built using the technology and teams acquired from Poynt in December 2020. GoDaddy Payments provides a fast and secure way for GoDaddy's ecommerce customers to get paid. The setup process is simple and quick, enabling customers to begin using GoDaddy Payments for processing their customers' transactions in minutes. Payments are processed securely and efficiently, with funds deposited into users' bank accounts the very next business day.

09:11 EDT LivaNova gets FDA approval for study to evaluate aura6000 to treat Sleep Apnea - LivaNova announced it has received approval from the U.S. Food and Drug Administration FDA to proceed with its investigational device exemption clinical study, "Treating Obstructive Sleep Apnea using Targeted Hypoglossal Neurostimulation " The OSPREY study will seek to demonstrate the safety and effectiveness of the aura6000 System, the LivaNova implantable hypoglossal neurostimulator intended to treat adult patients with moderate to severe obstructive sleep apnea. An innovative alternative to the traditional continuous positive airway pressure machine, the aura6000 System generates stimulation through a programmable, rechargeable and implantable pulse generator . The IPG is implanted in a subcutaneous pocket near the clavicle of the patient via an outpatient surgery. Mild stimulation pulses from the IPG are delivered via a lead to the hypoglossal nerve to stimulate the tongue during sleep and help keep the patient's airway open. With the aura6000, there are no masks, hoses or mouthpieces connected to the patient during sleep. "The aura6000 is designed to maintain muscle tone of the tongue and upper airway so that airway obstruction and resulting sleep apnea are significantly reduced or eliminated," said Dr. Atul Malhotra, Professor of Medicine at University of California, San Diego and Principal Investigator for OSPREY. "During the OSPREY study, we will evaluate the apnea-hypopnea index responder rate of subjects with device stimulation activated to determine whether it is statistically significantly higher than the rate of subjects without stimulation. We will also evaluate the overall safety and efficacy of the device in its ability to treat patients with OSA."

09:10 EDT Nielsen, IHS Markit announce strategic relationship - Nielsen (NLSN) announced a strategic relationship with IHS Markit (INFO). Through this collaboration, Nielsen will integrate comprehensive automotive data from Polk Automotive Solutions by IHS Markit into its audience and outcomes measurement solutions. Leveraging Nielsen offerings, advertisers will have a clearer understanding of today's auto consumers, empowering them to make more effective, data-driven marketing decisions about engaging with auto audiences.

09:08 EDT Dogness International expands sales activities at Petco - Dogness (DOGZ) announced it has delivered more than 3,000 of its 2L programmable automatic dog and cat feeders in June, with delivery of approximately another 1,000 units expected over the next two weeks. Petco (WOOF) already carries an assortment of Dogness products in select stores and online, including the Dogness Smart CAM Feeder, Smart Fountains, Travel Bottles, and more. The delivery of the Dogness 2L programmable automatic dog and cat feeders is the first Dogness product to enter all of Petco's 1,600 retail stores, with additional availability online on the popular Petco.com e-commerce site.

09:07 EDT Wabtec, GM to commercialize Ultium battery and HYDROTEC for fuel cell solutions - Wabtec (WAB) and General Motors (GM) announced they will collaborate to develop and commercialize GM's Ultium battery technology and HYDROTEC hydrogen fuel cell systems for Wabtec locomotives. "The rail industry is on the cusp of a sustainable transformation with the introduction of batteries and hydrogen to power locomotive fleets," said Rafael Santana, CEO and president of Wabtec. "Our FLXdrive locomotive, the world's first 100-percent battery powered locomotive, has proven its potential to slash carbon emissions by up to 30 percent when operating at 6 MWh. But we can't stop there. By working with GM on Ultium battery and HYDROTEC hydrogen fuel cell technologies, we can accelerate the rail industry's path to decarbonization and pathway to zero-emission locomotives by leveraging these two important propulsion technologies." Wabtec and GM signed a nonbinding memorandum of understanding to advance the two companies' shared vision of a zero-emissions future in transportation. Wabtec will bring its expertise in energy management and systems optimization to develop a solution for heavy haul locomotives that takes full advantage of GM's advanced technologies. "

09:06 EDT Google Cloud expands strategic relationship with Johnson Controls - Google Cloud (GOOG, GOOGL) announced an expanded relationship with Johnson Controls (JCI) that will involve the leading building technology and solutions company running SAP's (SAP) Enterprise Resource Planning Central Component environment on Google Cloud. Migrating its SAP ECC environment to the cloud has helped Johnson Controls modernize some of its most critical business systems and applications at scale, and will expand the company's use of sustainable cloud infrastructure.

09:04 EDT Audacy announces addition of BetQL Network in partnership with BetMGM - Audacy (AUD) announced the addition of new weekday programming on the "BetQL Network" as part of its multiplatform partnership with BetMGM (MGM). Beginning June 21, the network will launch "The Daily Tip," featuring Michael Jenkins and Chelsea Messinger, and "BetMGM Tonight," starring Ryan Horvat and Quinton Mayo. The "BetQL Network," which features sports betting programming heard across Audacy's portfolio of sports stations, can be heard on The Bet 1430AM in Denver, 93.1 HD3 in Los Angeles and The Bet 105.9 FM-HD2 in Chicago, as well as via the Audacy digital platform.

09:03 EDT Wabtec, General Motors to develop Ultium battery, HYDROTEC hydrogen fuel cells - Wabtec (WAB) and General Motors (GM) announced they will collaborate to develop and commercialize GM's Ultium battery technology and HYDROTEC hydrogen fuel cell systems for Wabtec locomotives. Wabtec and GM signed a nonbinding memorandum of understanding to advance the two companies' shared vision of a zero-emissions future in transportation. Wabtec will bring its expertise in energy management and systems optimization to develop a solution for heavy haul locomotives that takes full advantage of GM's advanced technologies. GM's Ultium battery technology is anticipated to provide the flexibility, efficiency, power and reliability needed for rail. Ultium Cells LLC, GM's joint venture with LG Energy Solution, is currently constructing battery cell plants in Ohio and Tennessee. GM's HYDROTEC hydrogen fuel cell power cubes are compact and easy to package and can be used in a wide range of applications, including locomotives. HYDROTEC fuel cell systems will be assembled from globally sourced parts by Fuel Cell Systems Manufacturing, LLC in Brownstown, Michigan, the manufacturing joint venture between General Motors and Honda (HMC).

09:02 EDT INVO Bioscience appoints Andrea Goren as CFO - INVO Bioscience announced the appointment of Andrea Goren as the Company's CFO. In a career approaching 27 years, Goren has extensive experience in numerous financial functions, including service as a public company CFO, company director, capital raising activities as well as mergers and acquisition experience. Goren has served as managing director and CFO of Phoenix Group, a New York City-based private equity firm specializing in micro-cap and nano-cap public companies. He served as vice president of Shamrock Group, the Roy Disney family private investment firm in London; and was a director at New York City-based Madison Capital Group, a corporate advisory firm focused on U.S. / European Union cross border transactions. Goren holds a Bachelor of Arts degree from Connecticut College in New London, Connecticut, and an MBA from the Columbia Business School in New York City.

09:01 EDT Del Taco up about 5% in pre-market to $11.12 on rising WallStreetBets focus

08:55 EDT Recursion Pharmaceuticals to hire up to 50 people in Toronto by year-end - Recursion announced its intention to soon launch its first major multidisciplinary expansion beyond its Utah headquarters, with plans to hire up to 50 people in Toronto by the end of 2021. Recursion has partnered with Toronto Global, a team of experienced business advisors assisting businesses around the globe expand into the Toronto Region, and the Canadian Trade Commissioner Service, both of which are supporting Recursion's investment in Toronto and Canada.

08:54 EDT W.R. Grace opens new lab in Indiana - W. R. Grace announced the opening of a new analytical lab at its U.S. colloidal manufacturing site, East Chicago, IN. "This investment positions Grace at the forefront of ongoing innovation and accelerates our responsiveness to the evolving needs of our customers' use of LUDOX in critical applications," said Sandra Wisniewski, President, Grace Materials Technologies. "We are excited to expand our footprint in the East Chicago community and have extended capabilities that will support continued global demand."

08:53 EDT DraftKings falls after Hindenburg report targets 'black market operations' - Shares of DraftKings are moving lower after Nathan Anderson's short selling firm Hindenburg Research published a report on the name. "We think DraftKings has systematically skirted the law and taken elaborate steps to obfuscate its black market operations. These violations appear to be continuing to this day, all while insiders aggressively cash out amidst the market froth," Hindenburg wrote. DraftKings trades at a 26 times last twelve months despite no expectation of earnings for years, "intense" competition and regulatory risk, the firm adds. Hindenburg said it has taken a short position in DraftKings shares "after extensive research." DraftKings in premarket trading is down 8%, or $4.07, to $46.55.

08:50 EDT Helius Medical appoints Andreeff as CEO, Mathiesen as CFO - Helius Medical Technologies announced that Dane Andreeff and Jeffrey Mathiesen have been appointed to the respective positions of President and Chief Executive Officer and Chief Financial Officer, effective June 14, 2021. Joyce LaViscount will continue to serve as the company's Chief Operating Officer. Andreeff has served as Helius' Interim President and Chief Executive Officer since August 2020 and as a member of the Company's Board of Directors since August 2017. Mathiesen served as a member of Helius' Board of Directors and Chair of the Company's Audit Committee from June 2020 to June 2021.

08:47 EDT ContextLogic up 5.9% in pre-market as 2nd highest trending ticker on StockTwits - Shares of ContextLogic are up another 5.9% at $11.93 in pre-market trading following yesterday's 12.7% rally. The stock is the second highest trending ticker on StockTwits in terms of message volume this morning.

08:45 EDT Manhattan Associates expands relationship with Hy-Vee - Manhattan Associates announced that the grocery chain Hy-Vee has chosen to implement Manhattan's transportation management system to improve the efficiency and visibility of its logistics network and assist with its supply chain operations. "Logistics processes are becoming increasingly complex, and there's no room for error when working with delivery for perishable goods," said Bob Howell, senior vice president, Americas, at Manhattan Associates. "We are proud to once again partner with this innovative grocer and provide them with a proven and reliable solution that will continuously ensure quality and accuracy. We are thrilled that Hy-Vee has chosen Manhattan's TMS technology and look forward to continuing our successful relationship."

08:44 EDT Paya Holdings set to join Russell 2000, Russell 3000 Indexes - Paya Holdings announced that Paya is scheduled to join the small-cap Russell 2000 Index and the broad-market Russell 3000 Index, as well as the appropriate growth and value style indexes, at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021.

08:41 EDT Corcept Therapeutics settles patent litigation with Sun Pharmaceutical - Corcept Therapeutics announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities resolving patent litigation related to Korlym, Corcept's medication for the treatment of patients with Cushing's syndrome. The litigation has been pending in the United States District Court for the District of New Jersey since 2019, shortly after Sun notified Corcept that it had submitted an Abbreviated New Drug Application to the United States Food and Drug Administration seeking approval to market a generic version of Korlym. In connection with the settlement, Corcept has granted Sun the right to sell a generic version of Korlym in the United States beginning October 1, 2034 or earlier under circumstances customary for settlement agreements of this type.

08:37 EDT Luokung Technology regains eligibility for inclusion in Micro Cap index - Luokung Technology announced that the U.S. Department of Defense, or DoD, has removed the Company's designation as a Communist Chinese Military Company. In addition, as a result of the omission of the Company from Executive Order 14032, which amends and supersedes Executive Order 13959 in imposing restrictions on trading shares of certain Chinese companies, Luokung and its shareholders are no longer subject to any restrictions pursuant to Executive Order 13959, as amended. DoD confirmed the foregoing to Luokung and to the U.S. District Court for the District of Columbia. In light of the foregoing, Luokung and the government Defendants have filed a joint stipulation to have the Company's lawsuit challenging the designation voluntarily dismissed, which will bring the lawsuit to a close. Luokung has regained eligibility for inclusion in the FTSE GEIS, or Micro Cap, index, and expects that it will be re-included in such index upon the open of the stock market on June 21.

08:35 EDT FedEx delivers 1.35M COVID-19 vaccine doses to Mexico - FedEx Express, a subsidiary of FedEx (FDX) announced that it has safely delivered 1.35 million Johnson & Johnson (JNJ) COVID-19 vaccine doses to Toluca, Mexico, in coordination with Direct Relief and the United States and Mexican governments.

08:33 EDT Digital Brands signs non-binding letter of intent to acquire Stateside - DBG announced that it has signed a non-binding letter of intent to acquire Stateside, a privately-owned global elevated basics brand. The parties intend to enter into a binding agreement within the next thirty days, with the closing envisaged in the third quarter of 2021. DGB expects to fund the acquisition with a combination of cash and equity to provide the Company the optimum financial flexibility in the future. Completion of the transaction is subject to customary conditions, including but not limited to the following key conditions: Execution of the Definitive Agreement; Completion of mutually satisfactory due diligence; and receipt of all required regulatory, corporate and third party approvals. Accordingly, there can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated.

08:29 EDT Fate Therapeutics appoints Mark Plavsic as Chief Technical Officer - Fate Therapeutics announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cGMP manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. As Chief Technical Officer, Mark will oversee the Company's manufacturing, technical, and supply chain operations. Prior to joining Fate Therapeutics, Dr. Plavsic served as Chief Technical Officer at Lysogene.

08:25 EDT Aemetis set to join Russell 3000 Index - Aemetis has been selected to join the broad-market Russell 3000 Index and the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective when Nasdaq trading opens on June 28, according to a preliminary list of additions posted on June 4.

08:23 EDT WeedMD to sell all shares of Starseed Medicinal to Final Bell Canada for C$2.5M - WeedMD announced it has signed and closed a definitive agreement to sell all the shares of its subsidiary's operating entity, Starseed Medicinal to Final Bell Canada for C$2.5M in cash. Starseed Medicinal is the licence holder for the Bowmanville Facility, which is licensed by Health Canada under the Cannabis Act for cultivation, processing and sale of dried cannabis and cannabis extracts, and to conduct research. Net proceeds of the sale will primarily be used by WeedMD to pay down its debt. The Company retains all aspects of its existing medical cannabis business, including its Starseed Medicinal brand. As a result of the facility optimization strategy initiated in early 2021 and the sale announced today, WeedMD is realizing material operational efficiencies by streamlining and consolidating its cultivation operations at its Strathroy, Ontario facility and processing and production activities at its Aylmer, Ontario site.

08:19 EDT Wireless Telecom signs over $2M in contracts with 4 new customers - Wireless Telecom announced that its Radio, Baseband, and Software product group, comprised of the company's CommAgility brand, has signed four new 5G software and services contracts in the first half of 2021. These four new contracts represent over $2M of new orders received in the first two quarters of 2021 and together have a total potential contract value of over $6M. "We are excited about the strong sales of 5G software in the first half of 2021 and continue to see a growing pipeline of 5G opportunities," said Tim Whelan, CEO of Wireless Telecom Group. "With 5G deployment in early stages and the unique 5G hardware and software solutions and capabilities of CommAgility, Wireless Telecom Group is well positioned to be a leader in technology development for 5G enterprise networks, commercial applications, and private networks."

08:16 EDT Codiak BioSciences expands executive leadership - Codiak BioSciences announced the promotion of Sriram Sathyanarayanan, Ph.D., who has led Codiak's preclinical research efforts for the past four years to Chief Scientific Officer. Additionally, Konstantin Konstantinov, Ph.D., who has led the company's manufacturing and process sciences since Codiak's inception, has been named Chief Technology Officer. Prior to this appointment, Sathyanarayanan was Senior Vice President, Preclinical Development. Konstantinov most recently held the position of Executive Vice President, Manufacturing and Process Sciences.

08:13 EDT OptimizeRx discusses 2021 strategic operating plan - OptimizeRx discusses aspects of the company's 2021 strategic operating plan which has been aligned with the pharma industry's market sizing opportunity across fast growing specialty therapeutic areas. "We continue to align our enterprise platform in support of our customers' growing needs. In particular, supporting pharma's engagement across specialty therapeutic areas such as oncology, immunology and cardiology has been a strategic imperative. We have seen a 600% rise in customer engagement in those three specialty areas in the last two years, which will make up at least 50% of our revenue going forward. We also have a stellar team of business development professionals working closely to secure additional partnerships and technology integrations with digital channels used by healthcare professionals beyond the EHR - scaling omni-channel connectivity at point-of-care. Our tech-first approach to focusing on the pain points of care delivery gives us a very compelling position in the market with all our stakeholders: patients, physicians and pharma," commented Will Febbo, CEO.

08:10 EDT First American settles with SEC over disclosure controls for $487,616 - First American Financial said it has reached a settlement with the United States Securities and Exchange Commission in connection with the previously disclosed information security incident that occurred during the second quarter of 2019 and which was the subject of the Wells Notice disclosed by the company in October 2020. Under the terms of the settlement, which resolves the matter, the company consented to the entry of an order finding a violation of Rule 13a-15 of the Securities Exchange Act of 1934, which requires issuers of registered securities to maintain effective disclosure controls. No other violations of the securities laws are alleged in the order, First American noted. The order requires the company to pay a civil penalty of $487,616 and to cease and desist from committing or causing any violations of Rule 13a-15.

08:10 EDT Eyenovia provides update on three Phase 3 programs - Eyenovia provided a corporate update on its pipeline with recent and upcoming milestones. Eyenovia previously announced initial topline data from its Phase 3 VISION-1 clinical trial. Today, the company is providing additional details from the study. The VISION-1 study evaluated the safety and efficacy of Eyenovia's MicroLine presbyopia microdose formulations versus placebo, all administered via the company's proprietary Optejet delivery Micro-Array Print technology. Key highlights from the 2% MicroLine dose include: a higher proportion of subjects met the primary endpoint of 3-line or greater improvement in near vision with 2% MicroLine as compared to placebo; a higher proportion of subjects achieved 2-line or greater improvement in near vision with 2% MicroLine as compared to placebo; 71% of patients reported a meaningful improvement in near vision according to an exit survey conducted by study investigators; all ocular AEs were trace to mild in severity and transient in nature. Importantly, fewer than 3% of study participants reported headache and brow ache. To support the submission of a New Drug Application, the company is on track to initiate a second Phase 3 registrational trial, VISION-2, later this year. VISION-2 will be a double-masked, placebo-controlled, cross-over superiority trial designed to enroll 120 patients randomized between 2% pilocarpine and placebo cohorts. Topline data is anticipated in mid-2022. Eyenovia is developing MydCombi for pharmacologic mydriasis. In March 2021, the FDA accepted Eyenovia's NDA, which was supported by two successful Phase 3 studies, MIST-1 and MIST-2. FDA has assigned a PDUFA target action date of October 28, 2021. If approved, Eyenovia anticipates marketing MydCombi with a small, targeted sales force. The company has also partnered with EVERSANA, a leading provider of commercial services to the global life sciences industry, to assist with the launch. Eyenovia previously disclosed two licensing agreements for its investigational treatment for the reduction of pediatric myopia progression, MicroPine: with Arctic Vision for Greater China and Korea, and Bausch Health for the United States and Canada.

08:08 EDT Aramark announces exclusive partnership with Talon - Aramark has secured an exclusive partnership with Talon, the maker of Adjustec waistband technology. The Adjustec technology is featured in Aramark's Authentic collection of shorts and pants to create greater comfort for wearers. This partnership marks the first time that this garment technology will be offered outside of a retail setting in uniform rental garments across a variety of industrial workspaces. Bringing innovative new technologies to market in the uniform rental space is one of the ways we are striving to improve the daily work life of our consumers," said Art Wake, President of Aramark Uniform Services. "Every advancement we champion has the end goal of improving quality for our clients. Talon's patented waistband technology will make our rental clothing the premium choice for fit and satisfaction." Adjustec improves customer satisfaction due to fewer sizing changes and greater fit accuracy. The waistbands are designed to adjust and recover, providing the same fit and comfort from the start of the day to the end.

08:06 EDT Enlivex Therapeutics issued European patent for Allocetra - Enlivex Therapeutics announced that the European Patent Office has issued European patent No. 3,258,943 covering Allocetra, the company's immunotherapy product candidate. The new patent's title is "COMBINATION IMMUNE THERAPY AND CYTOKINE CONTROL THERAPY FOR CANCER TREATMENT", and is expected to provide added intellectual property protection for therapeutic compositions of Allocetra and CAR-T immunotherapies for inhibition or reduction ofcytokine storms associated with CAR-T therapies for cancer. Allocetra is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications.

08:05 EDT OncoCyte enters software collaboration with Echelon Diagnostics - Echelon Diagnostics announced a strategic collaboration with Oncocyte. The two companies will work together to develop analytical software that can scale to support the commercial expansion of Oncocyte's tests and solutions that may help diagnosis and treatment of cancer.

08:03 EDT Amyris to acquire OLIKA, terms not disclosed - Amyris announced that it has executed a binding term sheet for the acquisition of award-winning, clean wellness company OLIKA. The acquisition furthers Amyris's growth and market leadership in clean health and beauty, and complements Amyris's family of consumer brands. Alastair Dorward will join Amyris as the Chief Brand Officer and will work closely with the Amyris leadership team to continue redefining the standards of sustainability and efficacy in clean beauty and wellness while accelerating growth and innovation for the Amyris family of consumer brands.

07:41 EDT SPAR Group announces resignation of three independent board members - SPAR Group announced that Arthur Baer, Igor Novgorodtsev, and Jeffrey Mayer, have resigned from the corporation's Board of Directors, effective June 9, 2021. Although the resigning Independent Directors expressed confidence in the CEO and the management team, as well as their respect and admiration for the fine leadership of the company's international and domestic joint venture partners, in their resignation letter to the corporation, the resigning Independent Directors said they were concerned over efforts by the company's two major shareholders that they believe could weaken Board independence, interfere with the operations of the company's business, and adversely affect the company's liquidity and minority shareholders.

07:39 EDT Capital One reports May net charge-offs 2.33% - Reports May 30-plus day performing delinquencies 1.69%.

07:37 EDT NRx Pharma reports data from ZYESAMI EAP - NRx Pharmaceuticals announced positive data from its ZYESAMI Expanded Access Protocol, or EAP. Overall, patients receiving at least one dose of ZYESAMI in addition to intensive care were alive at 28 days. This EAP provided an opportunity for many regional hospitals to offer ZYESAMI to its sickest patients, for whom no other options were available, and who could not enroll in a study due to additional risk factors. Fifty-six percent of patients enrolled were already receiving mechanical ventilation, and 44% were receiving non-invasive forms of ventilation, mostly high nasal flow cannula. NRx Pharmaceuticals Announces Positive Data Results from ZYESAMI Expanded Access Program"We initiated the ZYESAMI EAP at FDA's request, to gain real-world evidence from patient outcomes outside of the clinical trial environment. Working with 42 U.S. medical centers and hospitals, we were able to see the outcomes ZYESAMI(TM) provided to some of sickest of COVID-19 patients," said Jonathan Javitt, MD and Chairman of the Board, of NRx. "While vaccinations have markedly reduced the incidence of COVID-19 in some countries, effective medicines remain critical for the tens of thousands who continue contracting COVID-19 and the expanding numbers of variants associated with this virus."

07:35 EDT Cytokinetics announces completion of enrollment in METEORIC-HF study - Cytokinetics announced the completion of patient enrollment in METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil. METEORIC-HF is designed to evaluate the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity as determined by cardiopulmonary exercise testing in patients with heart failure with reduced ejection fraction. "We would like to thank the investigators and clinical site coordinators for their commitment to METEORIC-HF, particularly given the challenges they overcame enrolling a trial in the midst of a global pandemic," said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. "Based on recent interactions with FDA, we plan to submit the New Drug Application for omecamtiv mecarbil this year based on results from GALACTIC-HF. Results from METEORIC-HF are expected in early 2022 and may further elaborate on potential effects in patients with severe heart failure."

07:34 EDT Ocugen enters manufacturing partnership for US production of COVAXIN - Ocugen announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN to prepare for potential commercial manufacturing of COVAXIN for the US and Canadian markets. "We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants," said J.P. Gabriel, Ocugen's Senior Vice President, Manufacturing and Supply Chain. "Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech's strong track record of developing and commercializing vaccines globally and Jubilant's proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner."

07:32 EDT NN names Mike Felcher as CFO - NN (NNBR) named Mike Felcher as Senior Vice President and CFO effective July 1. Felcher will be assuming the CFO role from Tom DeByle, who will be retiring from his current role but will remain with the Company until June 30 to ensure a smooth transition. Felcher has served as NN's Chief Accounting Officer since June 2018. Prior to joining the Company, he served as the Vice President, North America CFO for JELD-WEN (JELD), a publicly held, global manufacturer of doors and windows, from 2013 to 2017. Before assuming his role at JELD-WEN, Felcher served as a Director of Finance for United Technologies Corp. following its acquisition of Goodrich Corporation in 2012. He also previously served in a variety of finance roles at Goodrich and began his career at PricewaterhouseCoopers in Boston.

07:31 EDT Alliance Data reports May net charge offs 5.2% vs. 5.2% last month - Reports May delinquency ratio 3.2% vs. 3.4% last month.

07:25 EDT Clearside report 'positive' safety results from OASIS Phase 1/2a trial of CLS-AX - Clearside Biomedical announced positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via Clearside's SCS Microinjector in six patients with neovascular age-related macular degeneration. The primary endpoints were achieved in Cohort 1, as the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug related treatment emergent adverse events observed throughout the study period. There were no signs of inflammation, no vasculitis, no intraocular pressure safety signals, no dispersion of drug into the vitreous, or any other drug related adverse events observed in any of the patients. The OASIS Safety Monitoring Committee has reviewed the data and the trial will advance to Cohort 2. Clearside expects to begin Cohort 2 patient screening for a dose of 0.1 mg CLS-AX in June 2021 with completion of this four month study period expected by the end of the year. "We are very encouraged by the Cohort 1 results of the OASIS trial and we are immediately beginning Cohort 2 enrollment as planned," said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. "The initial data from Cohort 1 clearly achieved our safety and tolerability endpoints. While still early and recognizing there are a limited number of patients, we believe the Cohort 1 data supports our hypothesis that the combination of targeted and compartmentalized suprachoroidal delivery and the potent pan-VEGF attributes of axitinib may facilitate an effective treatment option for patients suffering from wet AMD."

07:23 EDT XPO Logistics announces Meagan Fitzsimmons as CCO for spin-off company - XPO Logistics announced that Meagan Fitzsimmons has been appointed to the leadership team of GXO Logistics, the intended spin-off of XPO's logistics business. Fitzsimmons currently serves as XPO's chief compliance officer, or CCO, for the logistics segment. She will be responsible for GXO's global ethics and compliance infrastructure when the planned spin-off is complete.

07:20 EDT Apollo Funds to invest in Artius Acquisition to transition to net zero carbon - Artius Acquisition (AACQ) announced that certain funds managed by affiliates of Apollo Global Management,(APO) have agreed to invest up to $30M in Artius in support of its previously announced business combination with Origin Materials . "Origin Materials has developed a breakthrough, game changing technology that is poised to disrupt the materials supply chain and help companies globally achieve their net zero goals," said Boon Sim, Chief Executive Officer of Artius Acquisition. "Origin's carbon negative materials platform is supported by their customers - and now the focus is on scaling their technology to meeting growing global demand across a range of end product markets. This capital from the Apollo Funds combined with the pending completion of our merger with Origin is expected to provide the funding necessary to rapidly increase the supply of carbon negative materials and accelerate the global transition to net zero."

07:19 EDT Axsome Therapeutics announces planned NDA submission for AXS-14 - Axsome Therapeutics announced its plan to submit a New Drug Application for AXS-14 for the management of fibromyalgia following a pre-NDA meeting with the Food and Drug Administration. AXS-14 is a novel, oral, potent, and highly selective norepinephrine reuptake inhibitor. The NDA submission is currently anticipated in the fourth quarter of 2022 pending successful completion of manufacturing and other activities related to the product candidate. Acceptance of the NDA will be subject to the FDA's review of the complete filing. "Fibromyalgia is a debilitating central nervous system condition with limited treatment options. Results from two placebo-controlled trials demonstrate the potential for AXS-14 to significantly improve the symptoms of this serious condition," said Herriot Tabuteau, MD, CEO of Axsome. "We are excited by the potential of AXS-14 to expand the treatment options available to patients living with fibromyalgia, and look forward to completing manufacturing and other activities in anticipation of a planned NDA submission in the fourth quarter of next year." AXS-14 has completed two positive placebo-controlled trials for the management of fibromyalgia, a Phase 3 and a Phase 2 trial, which will be included in the planned NDA submission.

07:17 EDT Lithia Motors reports May revenue $2.1B, acquires five locations across Texas - Lithia Motors reported record May revenues of $2.1B and the acquisition of five locations across Texas. For the month of May 2021 compared to pre-pandemic 2019 levels, total revenues increased 89% to $2.1B and total same stores sales increase 26%. Comparing May 2021 results to 2020 pandemic-impacted levels, total revenues increased 104% and total same store sales increased 42%. "Our technology and team's ability to procure both new and used inventory, combined with continued strength in margins, drove strong performance," said Bryan Deboer, President and CEO. "With May same store growth of 20% in new vehicles and over 40% in used vehicles compared to pre-pandemic 2019 levels and service body and parts returning to 2019 levels, we are excited to be finishing up the first year of our 5-year plan to achieve $50 in EPS and $50 billion in revenue considerably ahead of plan." LAD also announced it has acquired the Southwest Kia Auto Group with five locations in the major metropolitan markets of Austin and Dallas, Texas. These locations are expected to add $350M in annualized revenues and brings LAD's total expected annualized revenues acquired to $7.5B since the launch of its 5-year plan. This transaction was financed using existing on-balance sheet capacity.

07:15 EDT Lexaria platform allows up to 3 fold boost in oral delivery of antiviral drugs - Lexaria Bioscience is pleased to announce positive results from its tolerability and pharmacokinetic animal study VIRAL-A20-2, evaluating DehydraTECH-enabled remdesivir and ebastine.These findings build upon Lexaria's recent announcement that remdesivir and ebastine processed with DehydraTECH were effective at inhibiting the COVID-19 SARS-CoV-2 virus using an in vitro screening assay in infected cells in its study VIRAL-C21-3. "These are the best results Lexaria has ever generated demonstrating our technology's ability to more effectively deliver antiviral drugs when taken orally," said Chris Bunka, CEO of Lexaria. "We are starting to see circulating drug levels in the bloodstream that are twice or even three-times higher with DehydraTECH than without, which could greatly enhance opportunities to treat viral infections via oral drug delivery."

07:13 EDT GasLog Partners announce new charter agreements with Total, Shell - GasLog Partners (GLOP) announced two new time charter agreements with leading global energy producers. The agreements include a one-year time charter for the GasLog Sydney with a subsidiary of Total, beginning this week, as well as an approximately 8-month time charter for the Solaris with a subsidiary of Royal Dutch Shell (RDS.A;RDS.B) beginning immediately following the conclusion of its initial multi-year charter with Shell in late July 2021 and extending through the end of Q1 2022. Paul Wogan, CEO of GasLog Partners, stated, "I am very pleased to announce these new charters with global energy majors. The agreements are at fixed daily rates of hire at returns in line with the historic long-term average, underscoring the strengthening LNG carrier spot market observed so far this year. Together they improve the Partnership's revenue and cash flow visibility, further balancing its operational and financial leverage."

07:10 EDT Autolus Therapeutics announces ILAP designation for obe-cel in UK - Autolus Therapeutics announced that it has received innovative licensing and access pathway, or ILAP, designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO1, or obe-cel, the company's CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory adult B-cell Acute Lymphocytic Leukemia in patients 18 years and older. "The ILAP designation for obe-cel, alongside the recent PRIority MEdicines designation from the European Medicines Agency is another step forward in accelerating the review process of this promising therapy," said Dr. Christian Itin, CEO of Autolus. "Obe-cel continues to show the potential to be differentiated on efficacy, durability and safety from other CAR T cell products and could change standard of care by offering a potentially curative therapy for r/r ALL."

07:08 EDT Ocwen partners with HomeFree-USA to expand hiring opportunities - Ocwen Financial announced that the company has partnered with HomeFree-USA to create a direct hiring pipeline for graduates of HomeFree-USA's Center for Financial Advancement program at historically black colleges and universities. The new program will create full-time employment opportunities for HBCU students who have successfully completed the CFA program. The two organizations are still planning the official recruitment process for eligible CFA scholars, and it is expected to launch later this year.

07:07 EDT Werewolf Therapeutics appoints Chulani Karunatilake as chief technology officer - Werewolf Therapeutics announced the appointment of Chulani Karunatilake, Ph.D. as Chief Technology Officer. Dr. Karunatilake brings more than 30 years of experience in Chemistry and Manufacturing Controls process and strategy development and will oversee manufacturing operations in the newly formed role. Dr. Karunatilake joins Werewolf from Maverick Therapeutics where he served as Senior Vice President of Technical Operations until the company's acquisition in March 2021.

07:04 EDT Marathon Petroleum announces preliminary results of tender offer - Marathon Petroleum announced the preliminary results of its "modified Dutch auction" tender offer, which expired at midnight, New York City time, at the end of the day on June 14. Based on the preliminary count by Computershare Trust Company, N.A., the depositary for the tender offer, a total of approximately 15.6M shares of MPC's common stock were validly tendered and not validly withdrawn at or below a purchase price of $63.00 per share, including approximately 10.4M shares that were tendered through notice of guaranteed delivery. These shares represent approximately 2.4% of MPC's outstanding common stock as of May 3. In accordance with the terms and conditions of the tender offer and based on the preliminary count by the depositary, MPC expects to accept for payment all of the approximately 15.6M shares of its common stock that were validly tendered and not validly withdrawn at a purchase price of $63.00 per share, for an aggregate cost of approximately $981M, excluding fees and expenses relating to the tender offer. As such, MPC expects that there will be no proration factor. On May 14 in connection with the closing of the sale of its Speedway business, MPC announced a total share repurchase authorization of $10B of its common stock with no expiration date. Upon completion of the tender offer, MPC expects to have approximately $9 billion remaining under its share repurchase authorization.

07:04 EDT VBL Therapeutics provides update on OVAL Phase 3 study of VB-111 - VBL Therapeutics provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec, for the treatment of platinum-resistant ovarian cancer. The company was notified by the Food and Drug Administration that clearance of new VB-111 batches for use in the U.S. is currently pending the completion of a technical review by the Chemistry, Manufacturing, and Controls group, which is evaluating the comparability of VB-111 manufacturing between different source sites. Until new batches are cleared, the company anticipates a temporary shortage of study drug supply for the U.S. Accordingly, recruitment of new patients in the U.S. will be temporarily paused. Treatment will continue as usual for all U.S. patients currently enrolled. To-date, the study has enrolled approximately 75% of the planned 400-patients. VBL recently amended the primary endpoint of OVAL based upon requested changes by the company that were reviewed by the FDA. OVAL now includes a second, separate primary endpoint, of progression free survival, in addition to the original primary endpoint of the trial, overall survival. Successfully meeting either primary endpoint is expected to be sufficient to support BLA submission.

07:02 EDT Denison Mines to acquire 50% ownership of JCU Exploration for $20.5M - Denison Mines announced that it has entered into a binding agreement to acquire 50% ownership of JCU Exploration Company from UEX Corporation, for cash consideration of $20.5M, following UEX's expected acquisition of JCU from Overseas Uranium Resources Development. UEX has entered into an amended purchase agreement with OURD to acquire 100% ownership of JCU, a wholly owned subsidiary of OURD, for cash consideration of $41M. JCU holds a portfolio of twelve uranium project joint venture interests in Canada, including a 10% interest in Denison's 90% owned Wheeler River project, a 30.099% interest in the Millennium project, a 33.8123% interest in the Kiggavik project, and a 34.4508% interest in the Christie Lake project.

06:51 EDT Northern Dynasty announces Pebble Partnership to undertake field program - Northern Dynasty reported that its 100%-owned U.S.-based subsidiary Pebble Limited is preparing crews and equipment to undertake a 2021 field program at the Pebble Project site in southwest Alaska this summer, with a focus on environmental management, sustainability and regulatory compliance. The Pebble Partnership's site office in Iliamna, Alaska will be the base of operations for a six-week, helicopter-supported program to begin in July, with additional field visits to occur throughout the year as required. "While our appeal of the November 2020 federal Record of Decision for Alaska's Pebble Project progresses, there is important work to be done to maintain and enhance our key asset, the Pebble deposit and surrounding mineral claims," said Ron Thiessen, Northern Dynasty president and CEO. "We are very proud of the continuity and quality of our environmental management, social engagement and regulatory compliance at the Pebble Project site, and fully intend to maintain that performance this year and into the future."

06:48 EDT Eli Lilly announces Emgality, Nurtec ODT head-to-head study - To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide, or CGRP, monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the prevention of migraine, Eli Lilly will be conducting a head-to-head study comparing once-monthly injectable Emgality with Nurtec ODT, an orally disintegrating tablet patients take every other day. CGRP is a protein in the brain thought to play a key role in migraine. Emgality binds to this protein, preventing it from attaching to the CGRP receptors, whereas Nurtec ODT blocks the receptor for this protein. The study, which is the first head-to-head clinical trial comparing two medications targeting CGRP, is a multi-site, randomized, double-blind, double-dummy, parallel-group Phase 4 study in patients who meet the International Classification of Headache Disorders, or ICHD, criteria for a diagnosis of episodic migraine with or without aura. There will be two treatment arms: Emgality 120 mg once-monthly injection, with an initial 240 mg loading dose, and Nurtec ODT 75 mg, taken every other day. The study's primary endpoint is 50% reduction in monthly migraine headache days. Enrollment is expected to begin later this year.

06:44 EDT Cathie Wood's ARK Investment bought 156.5K shares of KE Holdings on Monday

06:34 EDT Canadian National, Kansas City Southern jointly file documents with STB - CN (CNI) and Kansas City Southern (KSU) announced that they have jointly filed with the Surface Transportation Board certain documents requested by the STB in its June 8 Decision in STB Finance Docket No. 36514 to enable the STB to review the voting trust in connection with the definitive Merger Agreement between CN and KCS. These documents include: Written opinions of the financial advisors referenced in Section 4.16 of the Merger Agreement Debt Commitment Letters referenced in Section 4.17(a) of the Merger Agreement, including all exhibits and schedules; Section 5.1 of the company Disclosure Schedules referenced in Section 5.1(a) of the Merger Agreement, together with any other section(s) of the Company Disclosure Schedules that pertain to the company; Capital Allocation Policy referenced in Section 5.1(a) of the Merger Agreement and/or the "KCS pre-existing capital allocation policy" referenced in Applicants' May 26 Motion. With this filing, CN and KCS are one step closer to creating the premier railway for the 21st century. CN and KCS look forward to the STB's review and are confident that their voting trust will be approved. In response to the STB's request for information about KCS's pre-existing capital allocation policy, CN and KCS also submitted to the STB a Verified Statement from KCS Chief Financial Officer Michael W. Upchurch. In his statement, Upchurch comments: "The Board should expeditiously approve the CN voting trust. It is the same as the already approved CP trust. It has the same trustee. The Merger Agreement provides KCS with financial flexibility and freedom to undertake its capital and maintenance plans. Further, over 1400 stakeholders have supported the CN-KCS combination so far."

06:30 EDT Clean Energy jumps over 8% in pre-market on WallStreetBets focus - Shares of Clean Energy Fuels (CLNE) are up over 8% to $12.08 in pre-market trading amid continued attention and focus from retail investors on Reddit's WallStreetBets forum, where the stock was the most-mentioned ticker over the past 24 hours.

06:18 EDT Cathie Wood's ARK Investment discloses 211.5K shares of UiPath bought yesterday

06:17 EDT Cathie Wood's ARK Investment bought 183.2K shares of Etsy on Monday

06:11 EDT Radware and Involta announce partnership to deploy DDos Protection Service - Radware and Involta announced a recent partnership to deploy Radware's DDoS Protection Service to vital organizations nationwide. As an addition to Involta's existing robust suite of security offerings, Radware's DDoS Protection Service - recently ranked as a Leader in DDoS protection by Forrester Research - will expand the company's ability to meet rigorous security requirements across healthcare, manufacturing, financial services, and beyond.

06:09 EDT Biodesix announces availability of SARS CoV-2 neutralization antibody test - Biodesix announced the broad commercial launch of a SARS CoV-2 Neutralization Antibody Test. The test uses ELISA technology to detect circulating neutralizing antibodies against the receptor binding domain of the severe acute respiratory syndrome coronavirus 2 and is the first and only surrogate neutralizing antibody test with FDA Emergency Use Authorization.The cPass test represents an important diagnostic solution to understanding long-term protective immunity to SARS-CoV.

06:07 EDT AstraZeneca: Covid-19 vaccine effective against Delta variant - New data from Public Health England demonstrated COVID-19 Vaccine AstraZeneca offers high levels of protection against the Delta variant, AstraZeneca said in a statement. Real world data from PHE, published as a pre-print, demonstrated two doses of COVID-19 Vaccine AstraZeneca are 92% effective against hospitalization due to the Delta variant and showed no deaths among those vaccinated. The vaccine also showed a high level of effectiveness against the Alpha variant with an 86% reduction of hospitalizations and no deaths reported. The data suggest that vaccine effectiveness against milder symptomatic disease, although significant, was lower. Vaccine effectiveness against symptomatic disease was 74% against the Alpha variant and 64% against the Delta variant. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "This real world evidence shows that COVID-19 Vaccine AstraZeneca provides a high level of protection against the Delta variant, which is currently a critical area of concern given its rapid transmission. The data show that the vaccine will continue to have a significant impact around the world given that it continues to account for the overwhelming majority of supplies to India and the COVAX facility." Reference Link

06:02 EDT Quest Resource to acquire assets of environmental services company for $2.5M - Quest Resource Holding announced that it has signed a definitive agreement to acquire the assets of an Atlanta-based independent environmental services company. The total consideration of the acquisition at close is $2.5M, which will be paid in a combination of cash and an earn-out. During the Trailing Twelve Month period ending on March 31, the acquired assets, which mainly consist of customer contracts, are estimated to have produced Adjusted EBITDA of approximately $500,000. The acquisition is expected to be completed in the next 30 to 60 days, subject to customary closing conditions.

05:26 EDT Accenture to acquire engineering capabilities from DI Square, terms undisclosed - Accenture has entered into an agreement with DI Square to acquire the company's consulting capabilities for product lifecycle management, or PLM, and application lifecycle management, or ALM, systems integration. The acquisition will expand Accenture's engineering expertise for automotive and other manufacturing clients in Japan and other markets. Terms of the transaction were not disclosed. Accenture will acquire DI Square's PLM and ALM-related know-how and client contracts as well as take on approximately 70 DI Square professionals. They will join Accenture's Industry X group in Japan, which helps clients digitize their core operations including the design, development, manufacturing and servicing of smart connected products.

05:21 EDT Skanska signs $84M contract amendment to expand Portland International Airport - Skanska has, in a joint venture with Hoffman Construction, signed a contract amendment with the Port of Portland for improvements to the Portland International Airport in Portland, Oregon. Skanska's share of the contract amendment is worth $84M, which will be included in the U.S. order bookings for Q2. The amendment includes work on the terminal core expansion project, comprising structural, mechanical and electrical work and enclosure. Construction is underway. Substantial completion is scheduled for 2025.

05:17 EDT Elanco sells two facilities, physical assets to TriRx Pharmaceutical - TriRx Pharmaceutical Services announced an agreement to acquire two facilities from Elanco. The sites are located in Shawnee, Kansas and Speke, United Kingdom. The sale of the Shawnee and Speke sites includes the physical assets at both locations and the transfer of approximately 600 employees. The two companies have also entered into long-term supply agreements for both facilities to continue to manufacture existing Elanco products. The sale of the Shawnee facility is expected to close in the second half of 2021, while the Speke facility sale is expected to close by early 2022.

05:09 EDT Borr Drilling enters MoU to restructure Mexican joint ventures - Borr Drilling has five rigs working for joint ventures which are jointly owned with its Mexican partner providing integrated well services for Pemex. The services commenced in May 2019 and have provided Pemex with an incremental production of approximately 125,000 barrels of oil per day from 21 wells drilled so far. In the company's most recent meeting with Pemex management it has received a review of the performance and the cost efficiency of this operation. The integrated well services joint ventures have received a request for extension of this program, which in turn is expected to employ the five Borr Drilling rigs until the end of 2022. In connection with this extension, the company and its Mexican partner have entered into a memorandum of understanding, or MoU, to make certain changes in the structures of the joint ventures, where its Mexican partner will buy Borr Drilling's 49% stake of the integrated services JVs Opex and Akal. The transaction is expected to free up a gross amount of $28M for Borr Drilling, representing profits in the IWS JVs and some settlements of other payables, which is incremental to the dayrate earnings resulting from the provision of drilling services. Simultaneously, Borr Drilling will acquire an incremental 2% stake of the joint ventures performing drilling services from the Mexican partner, and by that hold a 51% majority ownership position. The drilling JVs will continue to earn day rates from its main customers Opex and Akal through regular drilling contracts. The company expects to close the transaction within Q3. As of the end of Q1 2021, Borr Drilling reported a receivable balance of $30.3M from its related parties, mainly representing bareboat revenue and other earnings due from the drilling JVs. In addition, the drilling JVs has a working capital balance and retained profits attributable to Borr Drilling. The $28M gross settlement for the transaction is in addition to this amount. The cash generated by the company's 13 operating rigs is expected to cover the finance, stacking and G&A cash cost for Q3. Additionally, with improved regularity in payments from Pemex, continued operation of Borr Drilling's rigs in Mexico until 2022, the proceeds from the sale of the IWS JVs, and an overall activity for the company in excess of 13 rigs should provide the company with sufficient liquidity runway until the current debt maturities in 2023. The company is also optimistic about re-activations of additional warm stacked rigs due to improved market conditions.